AHK-Cu (Copper Tripeptide-2): What the Research Actually Shows


Affiliate Disclosure


This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content.
Full policy →

Educational Notice

This article is written for researchers, formulators, clinicians, and informed consumers seeking to understand the published evidence on AHK-Cu (alanyl-histidyl-lysine copper complex, Copper Tripeptide-2). It is not medical advice, a treatment recommendation, or an endorsement of any product. AHK-Cu is a cosmetic ingredient — not a pharmaceutical drug — and is not evaluated by the FDA for safety or efficacy. Consult a qualified dermatologist or healthcare professional before making decisions about your skin health.

A Comprehensive Evidence Review for Researchers, Formulators, and Informed Consumers

AHK-Cu is frequently encountered in ingredient lists and formulator discussions as though it were a variant of GHK-Cu — the copper tripeptide with the longest research history in cosmetics and the broadest published evidence base in the category. The two are related but distinct. They share copper chelation and a tripeptide structure, and both signal fibroblast collagen synthesis through overlapping pathways. But they are different sequences, with different copper binding characteristics, different biological activity profiles in published studies, and substantially different evidence bases. GHK-Cu has decades of independent academic research behind it. AHK-Cu has preclinical and in vitro data — some of it promising — and no published human clinical trials.

AHK stands for alanine-histidine-lysine: a three-amino acid sequence forming the tripeptide core that chelates copper(II) ions. GHK stands for glycine-histidine-lysine — the difference is the first amino acid only (alanine versus glycine), but that single substitution meaningfully changes the peptide’s geometry, copper binding affinity, biological receptor interactions, and pharmacological profile. These are not interchangeable compounds, and the evidence from GHK-Cu studies does not automatically transfer to AHK-Cu.

This article examines AHK-Cu on its own terms — what the published evidence actually shows for this specific compound, where it differs from GHK-Cu, and what the evidence picture looks like for each delivery route including the injectable route, which has more pharmacological plausibility for copper tripeptides than for palmitoylated cosmetic peptides.

Quick Facts

INCI Name

Copper Tripeptide-2

Peptide Sequence

AHK-Cu: Ala-His-Lys complexed with Cu²⁺ (vs. GHK-Cu: Gly-His-Lys)

Mechanism Class

Carrier peptide (copper) — collagen stimulation, wound healing enzyme activation via copper delivery

Evidence Tier

Preclinical Only

Regulatory Status

Cosmetic ingredient — not a drug. No FDA approval or evaluation required.

WADA Status

Not prohibited

Molecular Weight

~409 Da (peptide component) — below the 500 Da passive penetration threshold; copper complex may alter effective penetration profile

Not to Confuse With

GHK-Cu (Copper Tripeptide-1) — different sequence, different evidence base, far more published research

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

What Is AHK-Cu?

AHK-Cu (INCI: Copper Tripeptide-2) is a synthetic copper-chelating tripeptide consisting of alanine, histidine, and lysine complexed with a copper(II) ion. It belongs to the same category as GHK-Cu (Copper Tripeptide-1) — copper-binding tripeptides that deliver bioavailable copper to skin tissue — but is a structurally distinct compound with its own chemistry, receptor interactions, and evidence profile.

The copper(II) ion chelated by the AHK tripeptide is not incidental — it is integral to the compound’s proposed mechanism. Copper is a required cofactor for several enzymes central to skin tissue remodeling: lysyl oxidase (LOX), which cross-links collagen and elastin fibrils to give them structural tensile strength; superoxide dismutase (Cu/Zn-SOD), an antioxidant enzyme; and ceruloplasmin, involved in iron metabolism. By delivering copper in a peptide-chelated, bioavailable form, AHK-Cu aims to support the enzymatic infrastructure for collagen and elastin synthesis and maintenance, not just to signal fibroblasts via matrikine pathways.

At approximately 409 Da (peptide component alone), AHK-Cu’s molecular weight sits below the 500 Da passive penetration threshold — a meaningful advantage over palmitoylated peptides like palmitoyl tripeptide-1 (583 Da) and original Matrixyl (802 Da). The copper complex formation adds to the effective molecular size, but the overall mass remains in a range where passive penetration through intact stratum corneum is more feasible than for higher-molecular-weight cosmetic peptides.

Origins and Development

The copper tripeptide category traces its origins to Loren Pickart’s work identifying GHK (glycine-histidine-lysine) as an endogenous copper-binding peptide in human plasma albumin in 1973, followed by decades of research characterizing GHK-Cu’s roles in wound healing, tissue remodeling, and skin biology. AHK-Cu emerged as a related compound of interest — the AHK sequence (alanine-histidine-lysine) was examined in the context of copper tripeptide biology as researchers explored whether other histidine-containing tripeptides could form stable copper complexes with similar biological activity.

Unlike GHK-Cu, which was identified as an endogenous human plasma peptide with a natural biological role before its cosmetic potential was developed, AHK-Cu does not have the same established endogenous identity. It is a synthetic compound designed based on structural similarity to GHK-Cu rather than isolated from a natural biological source. This distinction matters for interpreting the evidence: GHK-Cu’s extensive research program builds on a compound with known endogenous biology; AHK-Cu’s evidence starts from in vitro and preclinical characterization of a synthetic analog.

AHK-Cu vs. GHK-Cu: The Distinction That Matters

The single amino acid difference — alanine at position 1 in AHK versus glycine in GHK — creates meaningful differences in the compounds’ chemistry and biology. These are not interchangeable, and the extensive GHK-Cu evidence base does not transfer to AHK-Cu.

AHK-Cu (Copper Tripeptide-2) GHK-Cu (Copper Tripeptide-1)
Sequence Ala-His-Lys (alanine at N-terminus) Gly-His-Lys (glycine at N-terminus)
INCI name Copper Tripeptide-2 Copper Tripeptide-1
Endogenous origin Synthetic — not identified as natural human plasma constituent Endogenous — identified in human plasma albumin; natural biological role characterized
Copper binding affinity Forms stable Cu²⁺ complex; binding constants characterized in vitro; somewhat lower affinity than GHK-Cu in comparative studies High affinity Cu²⁺ complex (Kₐ ~10⁻¹⁵ M); extensively characterized
Human clinical evidence None published Multiple independent published studies; decades of research
Evidence tier Preclinical only Pilot / limited human data (independent studies available)
Molecular weight ~409 Da (peptide) — below 500 Da threshold ~340 Da (peptide) — below 500 Da threshold

Plain English

AHK-Cu and GHK-Cu differ by one amino acid — like two words that differ by a single letter. Similar enough to have overlapping chemistry and some shared mechanisms, different enough that you can’t use GHK-Cu research to validate AHK-Cu claims. GHK-Cu has decades of human research behind it. AHK-Cu does not. This is the most important fact to understand about AHK-Cu when evaluating products that contain it.

Mechanism of Action

AHK-Cu’s proposed mechanisms follow the same general logic as GHK-Cu, since both are copper-chelating tripeptides with histidine at the central position — the residue primarily responsible for copper coordination. The copper(II) ion is chelated by the peptide in a square planar coordination geometry, and the complex is proposed to deliver bioavailable copper to skin tissue in a form usable by copper-dependent enzymes.

Lysyl oxidase (LOX) activation: LOX requires copper as a cofactor to catalyze the oxidative deamination of lysine and hydroxylysine residues in collagen and elastin, forming covalent cross-links that provide tensile strength to connective tissue fibrils. Without adequate copper, newly synthesized collagen and elastin cannot be properly cross-linked, reducing the structural integrity of the newly formed extracellular matrix. AHK-Cu, by delivering bioavailable copper, may support LOX activity and thereby improve the quality of collagen being synthesized — not just the quantity.

Plain English

Making collagen isn’t just about producing the protein — it also needs to be properly cross-linked to be structurally useful, the same way steel cables need to be twisted together to have tensile strength. Lysyl oxidase does that cross-linking, and it needs copper to work. AHK-Cu proposes to supply that copper. Whether it actually does so at topical concentrations in living skin is the unanswered question.

Antioxidant support via Cu/Zn-SOD: Superoxide dismutase (specifically the copper-zinc isoform) is a primary antioxidant enzyme that converts superoxide radicals to hydrogen peroxide, protecting against oxidative damage from UV radiation and metabolic processes. Cu/Zn-SOD requires copper at its active site. AHK-Cu may support SOD activity by providing copper in a bioavailable form, contributing to antioxidant defense in the dermis.

Matrikine signaling: The AHK tripeptide — independent of copper — may have some matrikine-like signaling activity. The histidine-lysine dipeptide component shares structural features with known matrikine sequences. In vitro data suggests AHK-Cu stimulates fibroblast collagen production beyond what would be explained by copper delivery alone, suggesting a receptor-mediated signaling component in addition to the enzymatic copper-delivery mechanism. The extent to which this is additive to the copper mechanism versus mechanistically distinct has not been well-characterized in published literature.

Key Research Areas and Studies

In Vitro Studies

Published in vitro studies on AHK-Cu are limited but include some data in peer-reviewed literature. A study examining copper tripeptide analogs, including AHK-Cu, demonstrated stimulation of procollagen I synthesis in human dermal fibroblast cultures, with dose-dependent responses at concentrations of 0.1–10 µM. The magnitude of collagen stimulation was generally comparable to GHK-Cu in the same assay conditions, though GHK-Cu showed greater consistency across concentrations. AHK-Cu also demonstrated antioxidant activity in cell-free radical scavenging assays, consistent with copper-mediated SOD support.

Studies comparing copper tripeptide binding affinities found that AHK-Cu forms stable copper complexes, though with somewhat lower binding constants than GHK-Cu. In wound-healing assays using scratch models in fibroblast monolayers, AHK-Cu accelerated gap closure at tested concentrations, consistent with the wound-healing biology attributed to the copper tripeptide category.

Animal Studies

Some animal model data exists for copper tripeptide analogs including AHK-Cu, primarily in wound healing models. Topical application of AHK-Cu to excisional wounds in rodent models has shown enhanced wound closure rates and improved histological parameters (collagen deposition, fibroblast density) compared to vehicle control in limited published studies. These findings support the general wound-healing rationale for the copper tripeptide category but do not constitute human clinical evidence.

Human Clinical Studies

No published human clinical trials specifically examining AHK-Cu for cosmetic anti-aging outcomes have been identified in PubMed-indexed literature. This is the fundamental evidence gap that separates AHK-Cu from GHK-Cu, which has multiple published human studies. The preclinical evidence is mechanistically coherent and biologically plausible, but without human clinical data, AHK-Cu sits firmly in the preclinical evidence tier regardless of the strength of its in vitro findings.

Evidence note: AHK-Cu is frequently marketed alongside or in place of GHK-Cu with claims implying equivalent evidence. No published human clinical trial exists for AHK-Cu. The in vitro and animal data is promising but does not substitute for human evidence. GHK-Cu has that human evidence; AHK-Cu does not. Products that list AHK-Cu and imply the same evidence depth as GHK-Cu are overstating what has been established for this specific compound.

Common Claims versus Current Evidence

Claim What the Evidence Shows Verdict
“Same as GHK-Cu” / equivalent copper peptide Different sequence (Ala vs. Gly at position 1), different endogenous biology, different binding constants, and critically different evidence bases. GHK-Cu has human clinical data; AHK-Cu does not. Related category, not interchangeable compounds. Incorrect — related but distinct; evidence does not transfer
“Stimulates collagen production” Supported in vitro — fibroblast collagen synthesis increases at tested concentrations. Animal wound healing models show consistent signals. No human clinical data. Supported preclinically; unconfirmed in humans
“Clinically proven anti-aging effects” No published human clinical trial exists for AHK-Cu. Any “clinical” claim for this compound that does not specify animal or in vitro data is unsupported. No human evidence — claim is unsupported
“Better penetration than GHK-Cu” AHK-Cu’s peptide molecular weight (~409 Da) is slightly higher than GHK-Cu (~340 Da), not lower. Both are below the 500 Da passive penetration threshold. Neither has a clearly established penetration advantage over the other in published independent human skin data. Incorrect on molecular weight; penetration comparison unestablished
“SC injection delivers superior results” No published SC injection data for AHK-Cu. Unlike palmitoylated peptides whose chemistry is optimized for topical delivery, copper tripeptides are water-soluble and not topical-delivery-specific — the SC injection rationale is somewhat stronger here than for palmitoylated compounds, but remains without evidence and raises systemic copper exposure considerations. No evidence; more pharmacological plausibility than palmitoylated peptides but still unsubstantiated

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

The Human Evidence Landscape

AHK-Cu sits at preclinical — the lowest evidence tier used for compounds in this cluster. This is not a judgment about the compound’s potential; it is a factual description of what has been published. The in vitro mechanistic evidence is coherent and biologically plausible. The animal data is supportive. The human data does not exist in published form. For a compound that has been commercially available in cosmetic formulations for years, the absence of a published human clinical trial is notable — though it is consistent with the general pattern in the cosmetic ingredient industry where proprietary compounds are often used commercially without the independent clinical trial investment that would be required for pharmaceutical registration.

For researchers and formulators evaluating AHK-Cu for inclusion in formulations, the honest position is: mechanistically plausible copper tripeptide with promising preclinical data and zero published human clinical evidence. It may be effective — the category biology supports the general approach — but that effectiveness has not been demonstrated in humans for this specific compound. Choosing AHK-Cu over GHK-Cu in a formulation represents a choice to use a less-evidenced compound when a better-evidenced alternative with overlapping mechanism is available.

One honest use case for AHK-Cu over GHK-Cu: cost. GHK-Cu is the more expensive active. If a formulator’s goal is to include a copper tripeptide in a formulation but budget constraints limit the GHK-Cu concentration achievable, AHK-Cu at higher concentration may be preferable to GHK-Cu at subtherapeutic concentration. This is a practical formulation consideration, not an evidence argument.

Safety, Risks, and Limitations

Topical Safety

AHK-Cu has not generated significant adverse event signals in commercial cosmetic use. Contact sensitization appears rare. The compound is well-tolerated topically at concentrations used in cosmetic formulations. No published toxicology studies specific to AHK-Cu in human skin are available in peer-reviewed literature, but the general copper tripeptide category has a favorable safety profile across decades of commercial use, and AHK-Cu appears consistent with this profile in commercial application.

One consideration specific to copper-containing compounds: excessive topical copper exposure could theoretically contribute to copper accumulation if absorption is significant over time. At cosmetic concentrations and with normal skin barrier function, systemic copper absorption from topical application is negligible. This is not a practical concern for normal cosmetic use, but it is relevant context for very high-concentration or very frequent applications.

Microneedling Safety Considerations

Microneedling with AHK-Cu solution is practiced in the self-experimentation community. The mechanistic rationale is similar to GHK-Cu microneedling — bypassing the stratum corneum increases dermal delivery, and the dermal fibroblast targets are accessible at microneedling depths. The copper delivery mechanism is consistent with microneedling delivery. No AHK-Cu-specific microneedling trial exists. Standard sterility concerns apply. AHK-Cu is water-soluble (unlike palmitoylated peptides), which simplifies reconstitution for microneedling use — it dissolves readily in bacteriostatic water without the vehicle considerations that affect palmitoylated compound delivery.

Subcutaneous Injection Safety

No published safety or pharmacokinetic data exists for SC injection of AHK-Cu. The SC injection rationale for AHK-Cu is somewhat more pharmacologically coherent than for palmitoylated peptides, for one specific reason: AHK-Cu is water-soluble, not designed exclusively for topical lipid barrier penetration. A water-soluble copper tripeptide administered subcutaneously would distribute systemically, and systemically circulating copper tripeptides could theoretically reach dermal fibroblasts and other target cells via the vasculature. This is a pharmacological argument for plausibility, not a safety endorsement or evidence of efficacy.

The safety considerations for SC copper tripeptide injection include: systemic copper exposure at doses and concentrations not established in published pharmacokinetic studies; no pharmaceutical-grade sterility of cosmetic-grade source material; no published adverse event data for this route; and the fundamental question of whether systemically distributed AHK-Cu actually accumulates in skin fibroblasts at concentrations sufficient for meaningful effect versus being cleared through normal copper metabolism pathways. These are not disqualifying concerns in the way that periorbital injection risks are for acetyl tetrapeptide-5, but they remain serious open questions in the absence of any published data.

Safety Note

SC injection of AHK-Cu has more pharmacological plausibility than SC injection of palmitoylated cosmetic peptides — the compound is water-soluble and not topical-delivery-specific. This makes it marginally more coherent as an injection candidate than argireline or Matrixyl. It does not make it safe, studied, or justified. No published pharmacokinetic data, no safety data, no efficacy data for SC administration, and non-sterile cosmetic-grade source material. The bar for injectable use is higher than “more plausible than some alternatives.”

Legal and Regulatory Status

AHK-Cu (Copper Tripeptide-2) is a cosmetic ingredient regulated under standard cosmetic frameworks in the US and EU. No FDA pre-market approval is required for cosmetic use. The compound appears in INCI lists as “Copper Tripeptide-2” — distinct from GHK-Cu, which appears as “Copper Tripeptide-1.” Reading the INCI number is essential for distinguishing the two compounds on product labels.

WADA status: not prohibited. No restrictions for athletes subject to anti-doping testing.

Research Protocols and Formulation Considerations

Concentration: No human clinical study provides a studied concentration anchor for AHK-Cu. In vitro data suggests biological activity at 0.1–10 µM. Commercial formulations typically use 1–3% by weight — the relationship between percentage in formulation and bioavailable concentration at target tissue is not established for this compound.

Stability: Copper tripeptides are water-soluble and generally stable across pH 5–7. Copper can catalyze oxidative reactions at alkaline pH or in the presence of hydrogen peroxide — compatibility with oxidizing actives (benzoyl peroxide, some vitamin C forms in high concentrations) should be assessed formulation-specifically. Storage in amber packaging reduces photocatalytic copper activity.

AHK-Cu vs. GHK-Cu selection: For formulators choosing between the two: GHK-Cu has the superior evidence base and established endogenous biology. AHK-Cu may offer a cost advantage. If the goal is to use the best-evidenced copper tripeptide, GHK-Cu is the defensible choice. If budget constraints make GHK-Cu impractical at effective concentrations, AHK-Cu at higher concentration based on available preclinical data is a reasonable formulation decision — with transparency that the evidence base is preclinical rather than clinical.

Copper interactions: Multiple copper-chelating compounds in the same formulation — AHK-Cu, GHK-Cu, and palmitoyl tripeptide-1 (which has a GHK copper-binding sequence) — can compete for available copper ions. The net effect on copper bioavailability from complex formulations containing multiple copper-binding peptides is not well-characterized. Simple formulations with one copper tripeptide at adequate concentration are likely more predictable than complex multi-copper-chelator systems.

Dosing and Delivery: What the Research Shows

Topical Application

No human clinical study establishes a topical concentration or protocol for AHK-Cu. Supplier recommendations typically suggest 1–3% in finished formulations, extrapolated from in vitro active concentration ranges and by analogy to GHK-Cu formulation practice. AHK-Cu’s molecular weight (~409 Da peptide component) is below the 500 Da passive penetration threshold, giving it a theoretical penetration advantage over palmitoylated cosmetic peptides — though the copper complex adds effective molecular size, and penetration through living human skin has not been directly measured in published studies.

Microneedling / Stamping

AHK-Cu’s water solubility makes it straightforward to dissolve for microneedling use — no special vehicle or emulsification is required. Community practice involves dissolving AHK-Cu powder in bacteriostatic water at 0.5–2% concentration for application during or after microneedling at 0.5–1.5 mm depth. No published trial data exists. The mechanistic rationale — dermal fibroblast copper delivery via microneedling channels — is coherent. Standard sterility caveats apply.

Subcutaneous Injection

No published pharmacokinetic or safety data for SC injection. AHK-Cu’s water solubility means it does not depend on lipid barrier interaction for delivery, making the SC route less pharmacologically incoherent than for palmitoylated peptides — but “less incoherent” is not evidence. The systemic copper delivery implications of SC injection have not been studied. Community use of injectable copper tripeptides (primarily GHK-Cu rather than AHK-Cu) exists, but AHK-Cu specifically has very limited community injection data relative to GHK-Cu. Non-sterile source material is the same fundamental limitation as for all cosmetic-grade compounds used injectably.

Delivery Routes in Self-Experimentation Communities

Route Community Use Evidence Key Risks
Topical serum/cream Moderate — less common than GHK-Cu topical use; appears in multi-copper-peptide formulations In vitro fibroblast and wound healing data; animal model data; no published human clinical trials Low — favorable safety profile in commercial use; source quality varies for raw powder purchases
Microneedling / stamping Practiced — water solubility makes reconstitution straightforward; less common than GHK-Cu microneedling No specific trials; mechanistic rationale coherent for dermal fibroblast copper delivery Moderate — sterility of source material; no published data for this specific compound via this route
SC injection Rare — some community reports; most copper tripeptide injection community use is GHK-Cu rather than AHK-Cu No published data; more pharmacologically coherent than palmitoylated peptides but unsubstantiated Moderate-higher — no safety data; systemic copper exposure implications unstudied; non-sterile source material; absent pharmacokinetic data

In self-experimentation communities, AHK-Cu occupies a secondary position to GHK-Cu — recognized as a copper tripeptide analog with less evidence, used in some multi-peptide formulations or as a GHK-Cu substitute when cost is a constraint. Community members with more technical backgrounds tend to recognize the evidence distinction and prefer GHK-Cu where possible. AHK-Cu’s main community appeal is in DIY formulations where a copper tripeptide is desired alongside other peptides at a lower per-gram cost than GHK-Cu.

Frequently Asked Questions

Q: What is AHK-Cu and how does it differ from GHK-Cu?

A: AHK-Cu (INCI: Copper Tripeptide-2, sequence Ala-His-Lys + Cu²⁺) is a synthetic copper-chelating tripeptide. GHK-Cu (INCI: Copper Tripeptide-1, sequence Gly-His-Lys + Cu²⁺) differs by a single amino acid at the N-terminus — alanine in AHK versus glycine in GHK. That single substitution produces meaningfully different copper binding characteristics, biological receptor interactions, and evidence bases. GHK-Cu is an endogenous human plasma peptide with decades of independent academic research and published human clinical trials. AHK-Cu is a synthetic compound with promising in vitro and animal data and no published human clinical trials. They are related compounds, not interchangeable ones.

Q: Does AHK-Cu have human clinical evidence?

A: No published human clinical trials for AHK-Cu have been identified in PubMed-indexed literature. The evidence base is preclinical — in vitro fibroblast studies showing collagen stimulation and antioxidant activity, and limited animal wound healing model data. This is the most important distinction from GHK-Cu, which does have published human clinical evidence. Products marketing AHK-Cu with claims that imply clinical proof are overstating the current evidence level for this specific compound.

Q: Why would anyone use AHK-Cu instead of GHK-Cu if GHK-Cu has better evidence?

A: The practical reason is cost. GHK-Cu is more expensive per gram than AHK-Cu. For formulators working within budget constraints, AHK-Cu at higher concentration may be a pragmatic choice over GHK-Cu at a subtherapeutic concentration that can't achieve meaningful tissue levels. This is a formulation economics argument, not an evidence argument. The honest framing is: if budget allows GHK-Cu at an effective concentration, it is the better-evidenced choice. If not, AHK-Cu is a preclinically supported alternative rather than a clinically equivalent one.

Q: How does AHK-Cu work?

A: AHK-Cu's proposed mechanisms parallel GHK-Cu's: copper delivery for lysyl oxidase (LOX) activation — LOX cross-links collagen and elastin fibrils for structural integrity and requires copper as a cofactor; support for copper-zinc superoxide dismutase (Cu/Zn-SOD), a key antioxidant enzyme; and possible matrikine-like fibroblast signaling independent of copper delivery. In vitro studies confirm fibroblast collagen stimulation at tested concentrations. Whether these mechanisms produce meaningful anti-aging outcomes in living human skin at topical concentrations has not been established in published clinical trials.

Q: Can AHK-Cu be used with microneedling?

A: Yes, and the rationale is mechanistically sound. AHK-Cu is water-soluble — it dissolves readily in bacteriostatic water without special vehicles, making it straightforward to prepare for microneedling use. The dermal fibroblast targets are at depths accessible to standard microneedling devices. No AHK-Cu-specific microneedling trial exists. Standard sterility concerns apply: cosmetic-grade AHK-Cu is not manufactured to pharmaceutical sterility standards, and introducing non-sterile solutions below the stratum corneum carries infection risk.

Q: Is SC injection of AHK-Cu more reasonable than for palmitoylated peptides?

A: Marginally more pharmacologically coherent, but still without evidence and not recommended. AHK-Cu is water-soluble and not specifically designed for topical lipid barrier penetration — unlike palmitoylated peptides whose chemistry is optimized for stratum corneum interaction, AHK-Cu doesn't lose its delivery rationale when injected systemically. A water-soluble copper tripeptide administered SC would distribute systemically and could theoretically reach dermal cells via vasculature. However: no published pharmacokinetic data, no safety data, no efficacy data for SC administration, and non-sterile cosmetic-grade source material. "More plausible than argireline SC injection" is a low bar that doesn't justify a recommendation.

Q: Can I use AHK-Cu and GHK-Cu in the same formulation?

A: You can, but with a caveat about copper competition. Both chelate copper ions — multiple copper-chelating compounds in the same formulation compete for available copper. The net effect on copper bioavailability from a formulation containing multiple copper tripeptides is not well-characterized in published literature. A simpler approach — one copper tripeptide at an adequate concentration — is more predictable than a multi-copper-chelator system. If using both, ensure total formulation copper availability is sufficient for both to form active complexes.

Q: Is AHK-Cu safe?

A: Topical AHK-Cu has a favorable safety profile in commercial cosmetic use — no significant adverse event signals, rare contact sensitization. The compound is well-tolerated. For microneedling use, source material sterility is the primary risk variable. For SC injection, there is no published safety data for this compound or route, and systemic copper exposure implications at injectable doses have not been studied. The topical safety profile established for cosmetic use does not extend to injectable applications.

PART-B:

AHK-Cu belongs to the copper tripeptide carrier peptide category alongside GHK-Cu — the compound it is most frequently confused with and the one with a substantially stronger evidence base. Both deliver bioavailable copper to skin tissue and signal fibroblast collagen synthesis through overlapping pathways. GHK-Cu has independent human clinical data; AHK-Cu does not. Palmitoyl tripeptide-1, while not a copper chelator, shares the GHK matrikine sequence and overlaps mechanistically in the collagen-stimulating direction without copper delivery. The table below shows all twelve compounds in the Skin & Cosmetic cluster for direct comparison.

Edit
Compound Type Primary Target Half-Life FDA Status WADA Status Evidence Tier Skin Target / Mechanism Typical Concentration Route Key Differentiator
Argireline (Acetyl Hexapeptide-3) Synthetic hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, SNAP-25 modulator) SNARE complex disruption / Botox-like wrinkle reduction (proposed) ~2–4 hours (topical; serum stability uncertain) Not FDA-approved (cosmetic ingredient, GRAS status for topical use) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression wrinkles (periorbital, forehead); muscle contraction inhibition (proposed topical analog to botulinum toxin mechanism) Typically 3–5% in cosmetic formulations Topical (creams, serums, cosmetics) Botox alternative for topical use. Synthetic SNARE inhibitor design. Limited published clinical efficacy vs. marketing claims
Matrixyl (Palmitoyl Pentapeptide-4) Synthetic pentapeptide conjugated to palmitic acid (Pal-GVQPR, collagen-stimulating) Procollagen upregulation (TGF-β pathway proposed); collagen I/III synthesis ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen remodeling; fine-line reduction; skin firmness (proposed) Typically 1–3% in cosmetic formulations Topical (creams, anti-aging serums) First-generation palmitoyl peptide anti-aging cosmetic. Synthetic TGF-β mimic. Limited independent clinical validation
Matrixyl 3000 (Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7 Blend) Synthetic blend of two palmitoyl peptides (Pal-GHK + Pal-GHKGQ, synergistic collagen/elastin remodeling) Dual collagen + elastin upregulation (proposed; broader TGF-β pathway activation) ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient blend) Not WADA-listed (topical cosmetic peptide blend) Tier 4 — Preclinical Only Dermal collagen and elastin remodeling; wrinkle depth and skin texture improvement (proposed) Typically 1–3% in cosmetic formulations (as synergistic blend) Topical (creams, serums, moisturizers) Second-generation peptide blend (Matrixyl + Palmitoyl Tetrapeptide-7). Synergistic formulation strategy. Limited peer-review studies
Snap-8 (Acetyl Octapeptide-3) Synthetic octapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-Gly-Gly-NH2, extended Argireline analog) Extended SNARE modulation / Acetylcholine inhibition (proposed Botox alternative) ~2–4 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression wrinkles (dynamic lines); neuromuscular junction relaxation analog (topical) Typically 2–5% in cosmetic formulations Topical (creams, serums, eye patches) Extended Argireline with two additional amino acids. Claimed improved potency vs. Argireline. Minimal peer-reviewed efficacy data
Leuphasyl (Hexapeptide-11) Synthetic hexapeptide (Palmitoyl-Pro-Asn-Thr-Asn-Leu-Ala, matrix metalloproteinase inhibitor proposed) MMP inhibition (skin-matrix degradation prevention); collagen preservation ~2–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Matrix preservation (anti-MMP); collagen/elastin fiber integrity; skin sagging prevention (proposed) Typically 2–4% in cosmetic formulations Topical (serums, firming creams) MMP-inhibitor design rationale. Alternative to collagen-upregulating peptides. Limited cosmetic industry data
Palmitoyl Tripeptide-1 (Pal-GHK) Synthetic tripeptide conjugated to palmitic acid (Pal-Gly-His-Lys, copper-chelating glycine-histidine-lysine) Copper chelation (collagen synthesis via Lox upregulation); wound healing reactivation ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen cross-linking; elastin remodeling; scar remodeling (proposed) Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) Topical (anti-aging serums, creams) Core component of Matrixyl and Matrixyl 3000. Copper-dependent mechanism. Palmitoyl modification enhances skin penetration
Palmitoyl Tetrapeptide-7 (Pal-GHKGQ) Synthetic tetrapeptide conjugated to palmitic acid (Pal-Gly-His-Lys-Gly-Gln, extended GHK variant with elastin-targeting residues) Elastin upregulation; integrin signaling activation (proposed); elastin-specific pathway ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Elastin remodeling (distinct from collagen pathway); skin elasticity and bounce; fine-line reduction (proposed) Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) Topical (anti-aging serums, firming creams) Extended GHK variant targeting elastin specifically. Synergistic with Palmitoyl Tripeptide-1 in Matrixyl 3000
Syn-Ake (Dipeptide Diethylaminobutyroyl Benzylamide Diacetate, Snake Venom Mimetic Peptide) Synthetic dipeptide-conjugate mimicking snake venom neurotoxins (synthetic neuro-blocking peptide) Neuromuscular junction analog blockade (topical snake venom mimic); acetylcholine inhibition ~2–4 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression line relaxation (periorbital wrinkles); dynamic wrinkle reduction (snake venom analog mechanism topical) Typically 1–3% in cosmetic formulations Topical (eye creams, serums, patches) Snake venom analog mechanism. Branded as natural-origin alternative to botulinum toxin. Limited clinical efficacy studies
Acetyl Tetrapeptide-5 (SNAP-25 Mimic) Synthetic tetrapeptide (Ac-Glu-Glu-Met-Gln, acetylated SNARE domain fragment) SNAP-25 modulation (neuromuscular junction-like topical effect, proposed) ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression lines (wrinkle reduction, proposed Botox analog); muscle-relaxation topical effect Typically 2–5% in cosmetic formulations Topical (anti-wrinkle serums, creams) Short SNAP-25 fragment. Purported Botox alternative via topical neuromuscular effects. Minimal published efficacy data
Palmitoyl Hexapeptide-12 Synthetic hexapeptide conjugated to palmitic acid (Pal-containing; proprietary exact sequence variable by supplier) Broad dermal remodeling (collagen + elastin + proteoglycan synthesis proposed) ~2–3 hours (topical) Not FDA-approved (cosmetic ingredient, proprietary formulations) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Multi-target dermal remodeling (collagen, elastin, GAGs); hydration and firmness (proposed) Typically 1–3% in cosmetic formulations Topical (moisturizers, anti-aging serums) Extended hexapeptide with broader claimed targets than Tripeptide-1 or Tetrapeptide-7. Proprietary variations limit standardization
AHK-Cu (Copper Tripeptide: Ala-His-Lys + Cu²⁺) Synthetic tripeptide-copper complex (alanine-histidine-lysine chelated to Cu²⁺, GHK-Cu analog) Collagen synthesis (copper-dependent lysyl oxidase activation); similar mechanism to GHK-Cu topical ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen remodeling; anti-aging (collagen-dependent wrinkle reduction); scar appearance improvement Typically 0.5–2% in cosmetic formulations Topical (serums, creams; AHK-Cu generally topical only, unlike GHK-Cu) GHK-Cu alternative with alanine substitution. More stable copper complex than GHK-Cu in some formulations. Cosmetic-grade copper peptide
Tripeptide-29 (Proprietary Sequence, Collagen-Targeting Peptide) Synthetic tripeptide (exact sequence proprietary; collagen I/III targeting proposed) Collagen-specific upregulation (proprietary mechanism); dermal matrix support ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Collagen I and III upregulation; skin resilience and firmness (proposed); anti-sagging Typically 1–2% in cosmetic formulations Topical (anti-aging creams, serums) Proprietary peptide composition (exact sequence not published). Limited third-party efficacy studies

Summary and Key Takeaways

AHK-Cu is a copper-chelating tripeptide with promising preclinical evidence and zero published human clinical trials. It is mechanistically coherent, biologically plausible, and frequently marketed with claims that borrow implicitly from the far more extensive GHK-Cu evidence base. The compounds are related but distinct — the single amino acid difference between them produces meaningfully different chemistry, binding characteristics, and evidence profiles. If you are choosing between AHK-Cu and GHK-Cu for a formulation or self-experimentation protocol, the honest answer is that GHK-Cu has the evidence and AHK-Cu does not yet. AHK-Cu may have a practical cost-based role as a lower-cost copper tripeptide option where GHK-Cu at effective concentration is not achievable — but this is a practical argument, not an evidence argument.

  • AHK-Cu (INCI: Copper Tripeptide-2, sequence Ala-His-Lys + Cu²⁺) is a synthetic copper-chelating tripeptide distinct from GHK-Cu (Copper Tripeptide-1, sequence Gly-His-Lys + Cu²⁺). One amino acid difference — meaningful consequences for chemistry, binding affinity, and biological profile.
  • GHK-Cu has decades of independent academic research and published human clinical evidence. AHK-Cu has in vitro fibroblast data, limited animal wound healing data, and no published human clinical trials. The evidence does not transfer between compounds.
  • Mechanism: copper delivery for lysyl oxidase activation (collagen cross-linking), Cu/Zn-SOD antioxidant support, and possible matrikine-like fibroblast signaling. Mechanistically coherent. Preclinically supported. Clinically unproven in humans.
  • Molecular weight (~409 Da peptide component) is below the 500 Da passive penetration threshold — a theoretical penetration advantage over palmitoylated cosmetic peptides, though water-soluble and does not require palmitoyl delivery modification.
  • Topical use at 1–3% is the evidence-consistent approach (no human studied concentration exists — this extrapolates from in vitro ranges and GHK-Cu practice). Microneedling is mechanistically coherent. SC injection is more pharmacologically plausible than for palmitoylated peptides (water-soluble, not topical-delivery-specific) but has no published evidence or safety data.
  • Practical formulation consideration: AHK-Cu may be used as a lower-cost copper tripeptide alternative to GHK-Cu where budget constraints exist — with the transparency that the evidence base is preclinical rather than clinical.
  • Multiple copper-chelating compounds in the same formulation compete for available copper ions — simple formulations with one copper tripeptide at adequate concentration are more predictable than complex multi-copper-chelator systems.
  • WADA: not prohibited. INCI: Copper Tripeptide-2. Regulatory: cosmetic ingredient, not a drug.

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Selected References and Key Studies

  1. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID 29986520 — GHK-Cu biology; provides context for the copper tripeptide category
  2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PMID 26065009
  3. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327–45. PMID 19624730
  4. Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016
  5. Tenaud I, et al. Zinc, copper and selenium in the skin. Eur J Dermatol. 1999;9(4):289–300. PMID 10356410 — copper biology in skin context
  6. Rucker RB, Kosonen T, Clegg MS, et al. Copper, lysyl oxidase, and extracellular matrix protein cross-linking. Am J Clin Nutr. 1998;67(5 Suppl):996S–1002S. PMID 9587135 — LOX copper cofactor mechanism

Further Reading and References

Disclaimer

This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing in this article should be interpreted as an endorsement of any cosmetic product, formulation, or delivery method.

AHK-Cu (Copper Tripeptide-2) is a cosmetic ingredient, not an FDA-approved drug. It has not been evaluated by the FDA for safety or efficacy. AHK-Cu and GHK-Cu (Copper Tripeptide-1) are distinct compounds — evidence from GHK-Cu research does not automatically apply to AHK-Cu.

All citations link to primary sources where available. Readers are encouraged to evaluate the evidence independently and consult a qualified dermatologist or healthcare professional before making decisions about skin care.

Resources & Further Research

Where to Go From Here

The services below have been selected by the Peptidings editorial team as resources worth your time, based on evidence standards, clinical oversight, and relevance to the compound covered above.

Affiliate disclosure: Peptidings may earn a commission if you purchase or subscribe through these links, at no cost to you. This never influences our evidence assessments, evidence tier classifications, or editorial coverage. Full disclosure policy →

Telehealth Options

Happy Head

A telehealth platform founded by board-certified dermatologists specializing in hair loss. Offers custom-compounded topical and oral treatments including finasteride, dutasteride, and minoxidil combinations — prescribed and personalized by physicians, delivered to your door.

View Treatment Options →

All links above are affiliate links. We may earn a commission if you subscribe, at no cost to you.

Scroll to Top